TY - JOUR
T1 - Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice
AU - Palladino, Claudia
AU - Gómez, María Luisa Navarro
AU - Soler-Palacín, Pere
AU - González-Tomé, María Isabel
AU - De Ory, Santiago J.
AU - Espiau, María
AU - Hoyos, Santiago Pérez
AU - León-Leal, Juan Antonio
AU - Méndez, María
AU - Moreno-Pérez, David
AU - Guasch, Claudia Fortuny
AU - Sierra, Antoni Mur
AU - Guruceta, Itziar Pocheville
AU - Guillén, Santiago Moreno
AU - Briz, Verónica
PY - 2015/10/23
Y1 - 2015/10/23
N2 - © Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved. Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
AB - © Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved. Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
KW - adolescents
KW - children
KW - HAART
KW - HIV-1
KW - maraviroc
U2 - 10.1097/QAD.0000000000000819
DO - 10.1097/QAD.0000000000000819
M3 - Article
SN - 0269-9370
VL - 29
SP - 2155
EP - 2159
JO - AIDS
JF - AIDS
IS - 16
ER -